KBC Group
CTKB icon

KBC Group’s Cytek Biosciences CTKB Stock Holding History

KBC Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,884
Closed -$26K – 1861
2024
Q1 		$26K Hold
3,884
– – ﹤0.01% 1796
2023
Q4 		$35K Hold
3,884
– – ﹤0.01% 1734
2023
Q3 		$21K Sell
3,884
-1,333
-26% -$10.7K ﹤0.01% 1875
2023
Q2 		$45K Buy
+5,217
New +$46.8K ﹤0.01% 1388

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

KBC Group's CTKB Position: Q2 2024 in Review

KBC Group sold out of Cytek Biosciences (CTKB) in Q2 2024, closing a stake of 3,884 shares — an estimated $26K sold.

KBC Group first reported a position in CTKB in Q2 2023 and held it in 4 quarters. The position peaked at $45K in Q2 2023. 128 funds tracked by Wall St. Rank hold CTKB as of Q2 2024.

  • KBC Group reported no remaining Cytek Biosciences position as of Q2 2024 after selling out during the quarter.
  • KBC Group sold 3,884 Cytek Biosciences shares in Q2 2024, an estimated $26K.
  • KBC Group first reported a position in Cytek Biosciences in Q2 2023 and held it in 4 quarters.
  • KBC Group's Cytek Biosciences position peaked at $45K in Q2 2023.
  • 128 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2024.

Based on KBC Group's 13F filing for Q2 2024, filed 17 Jul 2024.